Who
Charles A. Rowland Jr.
Director
Company insider
Files Form 4 as: Director, Generation Bio Co; Director, Viking Therapeutics; Director, Orchard Therapeutics; Director, Nabriva Therapeutics; Director, Blueprint Medicines; Director, Nabriva Therapeutics; Director, Vitae Pharmaceuticals; Director, Dnib Unwind.
In numbers
- Trades disclosed
- 194
- Buys
- 13
- Sells
- 10
- Bought
- $2.4M
- Sold
- $9.8M
- Companies
- 11
- Companies where not an officer
- 9
- First trade
- 25 Jan 2008
- Last trade
- 9 Feb 2026
- Last filed
- 9 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio CoBiotechnology | SEC FORM 4 Code U | —53,475 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —3,000 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —4,246 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —3,000 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —4,246 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —5,200 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —1,500 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —1,920 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —2,500 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative | SEC FORM 4 Code D | —6,000 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —5,200 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —1,500 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —1,920 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —2,500 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Cooption or derivative · Biotechnology | SEC FORM 4 Code D | —6,000 | filing |
| 9 Feb 2026filed 9 Feb 2026 | Generation Bio Co | SEC FORM 4 Code U | —53,475 | filing |
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,150 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,400 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,400 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | VKTX Viking TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,150 at $0.00 | filing |
News
Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 YearsVKTX · fool.com · 20 Oct 2026Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2VKTX · fool.com · 20 Oct 2026Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.VKTX · fool.com · 18 Oct 2026
0 headlines in the last 90 days name Charles A. Rowland Jr.; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.